産後うつ病治療市場：治療タイプ別、流通別-2025～2030年の世界予測

産後うつ病治療市場は、2023年に9億4,854万米ドルと評価され、2024年には10億2,686万米ドルに達すると予測され、CAGR 8.74％で成長し、2030年には17億558万米ドルに達すると予測されています。

産後うつ病（PPD）治療には、出産後にうつ病を発症した母親の症状を緩和するためのさまざまな治療介入が含まれます。このセグメントでは、抗うつ薬やホルモン療法などの薬理学的アプローチと、心理療法や生活習慣の改善などの非薬理学的戦略の両方が重視されています。このような治療の必要性は、新生児の約10～20％が世界的に罹患しているというPPDの有病率と、母体と新生児の健康に及ぼすその重大な影響に対する認識の高まりによって強調されています。これらの治療の適用は、症状の重篤度、医療へのアクセス、認知度によって大きく異なるため、それぞれに合ったアプローチの必要性が浮き彫りになっています。最終用途の範囲には、主に病院、産科クリニック、精神保健センター、在宅ケアの設定が含まれます。市場成長の主要影響要因としては、啓発キャンペーンの増加、遠隔医療の進歩、医療インフラ支出の増加などが挙げられます。個別化医療や、特定の患者のニーズに対応するデジタルヘルスソリューションの開発にはビジネス機会があります。早期診断と治療アドヒアランスを促進するデジタルプラットフォームは特に有望です。しかし、メンタルヘルスを取り巻く社会的偏見、医療へのアクセス格差、メンタルヘルス治療に対する保険適用の制限などが、市場成長の課題となっています。臨床的理解や治療の潜在的副作用の限界は、採用率をさらに抑制しています。イノベーションは、非侵襲的な脳刺激技術、拡張現実ベースの治療介入、早期診断のためのAI主導型予測分析などのセグメントで盛んになる可能性があります。市場は、アンメットニーズを活かそうとする製薬企業の参入の増加や、より効果的な治療法が期待されるバイオテクノロジーの進歩によって進化しています。研究は、PPDの病因をより深く理解するための縦断的研究と、副作用が少なく有効性の高い新規治療の開発に注力すべきです。この市場の特質は、急速な技術革新と、影響が大きいにもかかわらずあまり議論されていないメンタルヘルスのセグメントに取り組む強い動機付けにあり、成長とインパクトの大きな機会を提供しています。

市場力学：急速に進化する産後うつ病治療市場の主要市場洞察を公開

産後うつ病治療市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネス機会の獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界中で妊娠に伴う気分障害の有病率の上昇
  • 抗うつ薬と会話療法に対する需要の高まり
  • PPD治療に対する規制機関からの承認の増加
• 市場抑制要因
  • 医療従事者の不足
• 市場機会
  • 遠隔医療と遠隔治療の利用可能性の増加
  • 新興市場におけるPPD治療のための研究活動の活発化
• 市場課題
  • 製品リコールに関する問題

ポーターのファイブフォース：産後うつ病治療市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォースフレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：産後うつ病治療市場における外部からの影響の把握

外部マクロ環境要因は、産後うつ病治療市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：産後うつ病治療市場における競合情勢の把握

産後うつ病治療市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス：産後うつ病治療市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、産後うつ病治療市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨：産後うつ病治療市場における成功への道筋を描く

産後うつ病治療市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネス機会を活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目セグメントを網羅した市場の包括的な分析を提供しています。

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力を評価します。

2.市場の開拓度：新興市場における成長機会を特定し、既存セグメントにおける拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品発売、未開拓の地域、産業の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で妊娠に関連する気分障害の有病率が上昇
    • 抗うつ薬と対話療法の需要増加
    • PPD治療に対する規制当局の承認増加
  • 抑制要因
    • 医療専門家の不足
  • 機会
    • 遠隔医療と遠隔診療の利用可能性の拡大
    • 新興市場における産後うつ病治療（PPD）の治療に関する研究活動の増加
  • 課題
    • 製品リコールに関する問題
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 産後うつ病治療市場：治療タイプ別

• イントロダクション
• 抗うつ薬
  • ブプロピオン
  • デシプラミン
  • エスシタロプラム
  • パロキセチン
  • セルトラリン
  • トラニルシプロミン
  • トリミプラミン
• 心理療法
  • 認知行動療法
  • 対人関係心理療法
  • 精神力動的心理療法
  • 解決志向短期心理療法

第7章 産後うつ病治療市場：流通別

• イントロダクション
• ドラッグストア
• eコマース
• 病院薬局
• 小売薬局

第8章 南北アメリカの産後うつ病治療市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋の産後うつ病治療市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカの産後うつ病治療市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Accord Healthcare Ltd.
• Alvogen Group Inc
• Anikem Laboratories
• AstraZeneca PLC
• Bausch Health Companies Inc.
• Cipla Limited
• Eli Lilly and Company
• GlaxoSmithKline PLC
• H. Lundbeck A/S
• Intas Pharmaceuticals Ltd.
• Lupin Ltd.
• Mylan N.V.
• Novartis AG
• Pfizer, Inc.
• Sage Therapeutics, Inc.
• Sebela Pharmaceuticals, Inc.
• Shionogi & Company, Limited
• Solvay S.A.
• Sumika Polymer Compounds（EU）Ltd
• Sun Pharmaceutical Industries Limited
• Teva Pharmaceuticals Industries Ltd.

LIST OF FIGURES

• FIGURE 1. POSTPARTUM DEPRESSION TREATMENT MARKET RESEARCH PROCESS
• FIGURE 2. POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. POSTPARTUM DEPRESSION TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. POSTPARTUM DEPRESSION TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. POSTPARTUM DEPRESSION TREATMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. POSTPARTUM DEPRESSION TREATMENT MARKET DYNAMICS
• TABLE 7. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY BUPROPION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DESIPRAMINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ESCITALOPRAM, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PAROXETINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY SERTRALINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TRANYLCYPROMINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TRIMIPRAMINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY INTERPERSONAL PSYCHOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHODYNAMIC PSYCHOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY SOLUTION-FOCUSED BRIEF PSYCHOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DRUG STORES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY E-COMMERCE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 37. BRAZIL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 38. BRAZIL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
• TABLE 39. BRAZIL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 41. CANADA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 42. CANADA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
• TABLE 43. CANADA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 44. CANADA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 45. MEXICO POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 46. MEXICO POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
• TABLE 47. MEXICO POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 48. MEXICO POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 49. UNITED STATES POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 50. UNITED STATES POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
• TABLE 51. UNITED STATES POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 52. UNITED STATES POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 53. UNITED STATES POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 54. ASIA-PACIFIC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 55. ASIA-PACIFIC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
• TABLE 56. ASIA-PACIFIC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 57. ASIA-PACIFIC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 58. ASIA-PACIFIC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 59. AUSTRALIA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 60. AUSTRALIA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
• TABLE 61. AUSTRALIA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 62. AUSTRALIA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 63. CHINA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 64. CHINA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
• TABLE 65. CHINA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 66. CHINA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 67. INDIA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 68. INDIA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
• TABLE 69. INDIA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 70. INDIA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 71. INDONESIA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 72. INDONESIA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
• TABLE 73. INDONESIA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 74. INDONESIA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 75. JAPAN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 76. JAPAN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
• TABLE 77. JAPAN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 78. JAPAN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 79. MALAYSIA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 80. MALAYSIA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
• TABLE 81. MALAYSIA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 82. MALAYSIA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 83. PHILIPPINES POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 84. PHILIPPINES POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
• TABLE 85. PHILIPPINES POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 86. PHILIPPINES POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 87. SINGAPORE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 88. SINGAPORE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
• TABLE 89. SINGAPORE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 90. SINGAPORE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 91. SOUTH KOREA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 92. SOUTH KOREA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
• TABLE 93. SOUTH KOREA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 94. SOUTH KOREA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 95. TAIWAN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 96. TAIWAN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
• TABLE 97. TAIWAN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 98. TAIWAN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 99. THAILAND POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 100. THAILAND POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
• TABLE 101. THAILAND POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 102. THAILAND POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 103. VIETNAM POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 104. VIETNAM POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
• TABLE 105. VIETNAM POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 106. VIETNAM POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 107. EUROPE, MIDDLE EAST & AFRICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 108. EUROPE, MIDDLE EAST & AFRICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
• TABLE 109. EUROPE, MIDDLE EAST & AFRICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 110. EUROPE, MIDDLE EAST & AFRICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 111. EUROPE, MIDDLE EAST & AFRICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 112. DENMARK POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 113. DENMARK POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
• TABLE 114. DENMARK POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 115. DENMARK POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 116. EGYPT POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 117. EGYPT POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
• TABLE 118. EGYPT POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 119. EGYPT POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 120. FINLAND POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 121. FINLAND POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
• TABLE 122. FINLAND POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 123. FINLAND POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 124. FRANCE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 125. FRANCE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
• TABLE 126. FRANCE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 127. FRANCE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 128. GERMANY POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 129. GERMANY POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
• TABLE 130. GERMANY POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 131. GERMANY POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 132. ISRAEL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 133. ISRAEL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
• TABLE 134. ISRAEL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 135. ISRAEL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 136. ITALY POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 137. ITALY POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
• TABLE 138. ITALY POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 139. ITALY POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 140. NETHERLANDS POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 141. NETHERLANDS POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
• TABLE 142. NETHERLANDS POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 143. NETHERLANDS POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 144. NIGERIA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 145. NIGERIA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
• TABLE 146. NIGERIA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 147. NIGERIA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 148. NORWAY POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 149. NORWAY POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
• TABLE 150. NORWAY POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 151. NORWAY POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 152. POLAND POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 153. POLAND POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
• TABLE 154. POLAND POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 155. POLAND POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 156. QATAR POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 157. QATAR POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
• TABLE 158. QATAR POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 159. QATAR POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 160. RUSSIA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 161. RUSSIA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
• TABLE 162. RUSSIA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 163. RUSSIA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 164. SAUDI ARABIA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 165. SAUDI ARABIA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
• TABLE 166. SAUDI ARABIA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 167. SAUDI ARABIA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 168. SOUTH AFRICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 169. SOUTH AFRICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
• TABLE 170. SOUTH AFRICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 171. SOUTH AFRICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 172. SPAIN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 173. SPAIN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
• TABLE 174. SPAIN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 175. SPAIN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 176. SWEDEN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 177. SWEDEN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
• TABLE 178. SWEDEN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 179. SWEDEN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 180. SWITZERLAND POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 181. SWITZERLAND POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
• TABLE 182. SWITZERLAND POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 183. SWITZERLAND POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 184. TURKEY POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 185. TURKEY POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
• TABLE 186. TURKEY POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 187. TURKEY POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 188. UNITED ARAB EMIRATES POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 189. UNITED ARAB EMIRATES POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
• TABLE 190. UNITED ARAB EMIRATES POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 191. UNITED ARAB EMIRATES POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 192. UNITED KINGDOM POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 193. UNITED KINGDOM POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
• TABLE 194. UNITED KINGDOM POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 195. UNITED KINGDOM POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 196. POSTPARTUM DEPRESSION TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 197. POSTPARTUM DEPRESSION TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

The Postpartum Depression Treatment Market was valued at USD 948.54 million in 2023, expected to reach USD 1,026.86 million in 2024, and is projected to grow at a CAGR of 8.74%, to USD 1,705.58 million by 2030.

Postpartum depression (PPD) treatment encompasses a range of therapeutic interventions designed to alleviate symptoms in mothers experiencing depression following childbirth. This sector emphasizes both pharmacological approaches, such as antidepressants and hormone therapy, and non-pharmacological strategies, including psychotherapy and lifestyle modifications. The necessity for such treatments is underscored by the increasing recognition of PPD's prevalence, affecting approximately 10-20% of new mothers globally, and its profound impact on both maternal and neonatal health. The application of these treatments varies significantly based on the severity of the condition, access to healthcare, and awareness levels, highlighting an immense need for tailored approaches. End-use scope primarily involves hospitals, maternity clinics, mental health centers, and home care settings. Key influencing factors for market growth include the rise in awareness campaigns, advancements in telemedicine, and increased healthcare infrastructure spending. Opportunities lie in developing personalized medicine and digital health solutions that cater to specific patient needs. Digital platforms that facilitate early diagnosis and treatment adherence are particularly promising. However, market growth is challenged by societal stigma surrounding mental health, disparities in healthcare access, and limited insurance coverage for mental health treatments. Limitations in clinical understanding and the potential side effects of treatments further constrain adoption rates. Innovation could thrive in areas such as non-invasive brain stimulation techniques, augmented reality-based therapeutic interventions, and AI-driven predictive analytics for early diagnosis. The market is evolving with increased participation from pharmaceutical companies keen to capitalize on unmet needs and advancements in biotechnology promising more effective treatment modalities. Research should focus on longitudinal studies to better understand the etiology of PPD and the development of novel therapeutics that offer better efficacy with fewer side effects. The market's nature is characterized by rapid innovation and a strong incentive to address a highly impacting yet often under-discussed mental health segment, presenting considerable opportunities for growth and impact.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Postpartum Depression Treatment Market

The Postpartum Depression Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prevalences of mood disorder associated with pregnancy across the globe
  • Growing demand for antidepressant medication and talk therapies
  • Increasing approvals from regulatory bodies for PPD treatment
• Market Restraints
  • Limited availability of medical professionals
• Market Opportunities
  • Growing availability of telehealth and telemedicine
  • Rising research activities for treatment of Postpartum Depression Treatment (PPD) in emerging markets
• Market Challenges
  • Issues related to product recalls

Porter's Five Forces: A Strategic Tool for Navigating the Postpartum Depression Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Postpartum Depression Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Postpartum Depression Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Postpartum Depression Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Postpartum Depression Treatment Market

A detailed market share analysis in the Postpartum Depression Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Postpartum Depression Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Postpartum Depression Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Postpartum Depression Treatment Market

A strategic analysis of the Postpartum Depression Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Postpartum Depression Treatment Market, highlighting leading vendors and their innovative profiles. These include Accord Healthcare Ltd., Alvogen Group Inc, Anikem Laboratories, AstraZeneca PLC, Bausch Health Companies Inc., Cipla Limited, Eli Lilly and Company, GlaxoSmithKline PLC, H. Lundbeck A/S, Intas Pharmaceuticals Ltd., Lupin Ltd., Mylan N.V., Novartis AG, Pfizer, Inc., Sage Therapeutics, Inc., Sebela Pharmaceuticals, Inc., Shionogi & Company, Limited, Solvay S.A., Sumika Polymer Compounds (EU) Ltd, Sun Pharmaceutical Industries Limited, and Teva Pharmaceuticals Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Postpartum Depression Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Treatment Type, market is studied across Antidepressant Drugs and Psychotherapy. The Antidepressant Drugs is further studied across Bupropion, Desipramine, Escitalopram, Paroxetine, Sertraline, Tranylcypromine, and Trimipramine. The Psychotherapy is further studied across Cognitive Behavioral Therapy, Interpersonal Psychotherapy, Psychodynamic Psychotherapy, and Solution-Focused Brief Psychotherapy.
• Based on Distribution, market is studied across Drug Stores, E-Commerce, Hospital Pharmacies, and Retail Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalences of mood disorder associated with pregnancy across the globe
    • 5.1.1.2. Growing demand for antidepressant medication and talk therapies
    • 5.1.1.3. Increasing approvals from regulatory bodies for PPD treatment
  • 5.1.2. Restraints
    • 5.1.2.1. Limited availability of medical professionals
  • 5.1.3. Opportunities
    • 5.1.3.1. Growing availability of telehealth and telemedicine
    • 5.1.3.2. Rising research activities for treatment of Postpartum Depression Treatment (PPD) in emerging markets
  • 5.1.4. Challenges
    • 5.1.4.1. Issues related to product recalls
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Postpartum Depression Treatment Market, by Treatment Type

• 6.1. Introduction
• 6.2. Antidepressant Drugs
  • 6.2.1. Bupropion
  • 6.2.2. Desipramine
  • 6.2.3. Escitalopram
  • 6.2.4. Paroxetine
  • 6.2.5. Sertraline
  • 6.2.6. Tranylcypromine
  • 6.2.7. Trimipramine
• 6.3. Psychotherapy
  • 6.3.1. Cognitive Behavioral Therapy
  • 6.3.2. Interpersonal Psychotherapy
  • 6.3.3. Psychodynamic Psychotherapy
  • 6.3.4. Solution-Focused Brief Psychotherapy

7. Postpartum Depression Treatment Market, by Distribution

• 7.1. Introduction
• 7.2. Drug Stores
• 7.3. E-Commerce
• 7.4. Hospital Pharmacies
• 7.5. Retail Pharmacies

8. Americas Postpartum Depression Treatment Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Postpartum Depression Treatment Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Postpartum Depression Treatment Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Accord Healthcare Ltd.
• 2. Alvogen Group Inc
• 3. Anikem Laboratories
• 4. AstraZeneca PLC
• 5. Bausch Health Companies Inc.
• 6. Cipla Limited
• 7. Eli Lilly and Company
• 8. GlaxoSmithKline PLC
• 9. H. Lundbeck A/S
• 10. Intas Pharmaceuticals Ltd.
• 11. Lupin Ltd.
• 12. Mylan N.V.
• 13. Novartis AG
• 14. Pfizer, Inc.
• 15. Sage Therapeutics, Inc.
• 16. Sebela Pharmaceuticals, Inc.
• 17. Shionogi & Company, Limited
• 18. Solvay S.A.
• 19. Sumika Polymer Compounds (EU) Ltd
• 20. Sun Pharmaceutical Industries Limited
• 21. Teva Pharmaceuticals Industries Ltd.